Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- (MitoRx), a platform biotechnology company developing novel ...

The stock's fall snapped a two-day winning streak.

The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...